AC Immune (NASDAQ:ACIU) Stock Price Passes Above 50 Day Moving Average – What’s Next?

AC Immune (NASDAQ:ACIU)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.39 and traded as high as $2.59. AC Immune shares last traded at $2.57, with a volume of 90,179 shares trading hands.

Analysts Set New Price Targets

ACIU has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Thursday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AC Immune has a consensus rating of “Hold” and an average target price of $7.50.

AC Immune Price Performance

The stock has a market cap of $268.67 million, a price-to-earnings ratio of -4.89 and a beta of 1.59. The company has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $2.71. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. The company had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. Research analysts expect that AC Immune will post -0.6 EPS for the current year.

Hedge Funds Weigh In On AC Immune

A number of large investors have recently bought and sold shares of the company. Acadian Asset Management LLC grew its stake in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after acquiring an additional 172,796 shares in the last quarter. Sei Investments Co. bought a new stake in shares of AC Immune in the second quarter worth $51,000. Private Advisor Group LLC acquired a new position in AC Immune during the third quarter worth $48,000. Susquehanna International Group LLP bought a new position in AC Immune in the third quarter valued at $63,000. Finally, Goldman Sachs Group Inc. increased its stake in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.